Tropolones as lead-like natural products: The development of potent and selective histone deacetylase inhibitors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 757-761

  Ononye, Sophia N ^a,b   Vanheyst, Michael D ^a   Oblak, E Zachary ^a,c   Zhou, Wangda ^a   Ammar, Mohamed ^a   Anderson, Amy C ^a   Wright, Dennis L ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

HDAC; isozyme selectivity; metalloenzyme; T lymphocyte cancer cell lines; thujaplicin; Tropolone

Indexed keywords

ALPHA TROPOLONE; ANTINEOPLASTIC AGENT; BETA TROPOLONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; ISOENZYME; NATURAL PRODUCT; ROMIDEPSIN; THUJAPLICIN; TRAPOXIN; TRICHOSTATIN A; TROPOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODIVERSITY; CANCER CELL CULTURE; CANCER GROWTH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LYMPHOID CELL LINE; METAL BINDING; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84881457855     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400158k     Document Type: Article

References (25)

1. Erdtman, H.; Gripenberg, J. Antibiotic substances from the heartwood of Thuja plicata Nature 1948, 161, 719
2. Liu, S.; Yamauchi, H. p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function Cancer Lett. 2009, 286 (2) 240-249
3. Liu, S.; Yamauchi, H. Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines Biochem. Biophys. Res. Commun. 2006, 351 (1) 26-32
4. Morita, Y.; Matsumura, E.; Okabe, T.; Fukui, T.; Shibata, M.; Sugiura, M.; Ohe, T.; Tsujibo, H.; Ishida, N.; Inamori, Y. Biological activity of α-thujaplicin, the isomer of hinokitiol Biol. Pharm. Bull. 2004, 27, 899-902
5. Lee, M.-J.; Kim, Y.; Kummar, S.; Giaccone, G.; Trepel, J. Histone deaceylase inhibitors in cancer therapy Curr. Opin. Oncol. 2008, 20, 639-649
6. Minucci, S.; Pelicci, P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 2006, 6, 38-51
7. Seidel, C.; Schmnekenburger, M.; Dicato, M.; Diederich, M. Histone deacetylase modulators provided by Mother Nature Genes Nutr. 2012, 7, 357-367
8. Flipo, M.; Charton, J.; Hocine, A.; Dassonneville, S.; Deprez, B.; Deprez-Poulain, R. Hydroxamates: Relationships between structure and plasma stability J. Med. Chem. 2009, 52, 6790-6802
9. Venkatesh, P.; Goh, E.; Zeng, P.; New, L.; Xin, L.; Pasha, M.; Sangthongpitag, K.; Yeo, P.; Kantharaj, E. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species Biol. Pharm. Bull. 2007, 30, 1021-1024
10. Balasubramanian, S.; Verner, E.; Buggy, J. J. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett. 2009, 280 (2) 211-221
11. Binaschi, M.; Boldetti, A.; Gianni, M.; Maggi, C.; Gensini, M.; Bigioni, M.; Parlani, M.; Giolitti, A.; Fratelli, M.; Valli, C.; Tereo, M.; Garattini, E. Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors ACS Med. Chem. Lett. 2010, 1, 411-415
12. Bressi, J.; Jennings, A. J.; Skene, R. J.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C.; Navre, M.; Gangloff, A. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N -(2-aminophenyl)benzamides Bioorg. Med. Chem. Lett. 2010, 20, 3142-3145
13. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases Structure 2004, 12 (7) 1325-1334
14. Noyori, R.; Makino, S.; Okita, T.; Hakyakawa, Y. A method for the generation of a synthetic equivalent of unsubstituted oxyallyl via the bromo ketone-iron carbonyl reaction. A new route to thujaplicins J. Org. Chem. 1975, 40, 806-807
15. Oblak, E. Z.; Bolstad, E.; Priestley, N.; Hadden, M. K.; Wright, D. The furan route to tropolones: Probing the antiproliferative effects of β-thujaplicin analogs Org. Biomol. Chem. 2012, 10, 8597-8604
16. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: From bench to clinic J. Med. Chem. 2008, 51 (6) 1505-1529
17. Marquard, L.; Gjerdrum, L.; Christensen, I.; Jensen, P.; Sehested, M.; Ralfkiaer, E. Prognostic significance of the therapeutics targets histone deacetylase 1, 2 and 6 and acetylated histone H4 in cutaneous T-cell lymphoma Histopathology 2008, 53, 267-277
18. Song, J.; Noh, J.; Lee, J. W.; Eun, J.; Ahn, Y.; Kim, S.; Lee, S.; Park, W.; Yoo, N.; Lee, J.; Nam, S. Increased expression of histone deacetylase 2 is found in human gastric cancer APMIS 2005, 113, 264-268
19. Bicaku, E.; Marchion, D.; Schmitt, M.; Munster, P. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling Cancer Res. 2008, 68, 1513-1519
20. Guan, J.-S.; Haggarty, S.; Giacometti, E.; Dannenberg, J.-H.; Joseph, N.; Gao, J.; Nieland, T.; Zhou, Y.; Wang, X.; Mazitschek, R.; Bradner, J.; DePinho, R.; Jaenisch, R.; Tsai, L.-H. HDAC2 negatively regulates memory formation and synaptic plasticity Nature 2009, 459, 55-60
21. Chang, S.; McKinsey, T.; Zhang, C.; Richardson, J.; Hill, J.; Olson, E. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress siganls and play redundant roles in heart development Mol. Cell. Biol. 2004, 24, 8467-8476
22. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; DeFrancesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. 2004, 101, 15064-15069
23. Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkühler, C.; Gallinari, P.; Carfí, A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain J. Biol. Chem. 2008, 283 (39) 26694-26704
24. Hagelkruys, A.; Sawicka, A.; Rennmayr, M.; Seiser, C. The biology of HDAC in cancer: The nuclear and epigenetic components Handb. Exp. Pharmacol. 2011, 206, 13-37
25. Obier, N.; Muller, A. Chromatin flow cytometry identifies changes in epigenetic cell states Cells Tissues Organs 2010, 191, 167-174